Peter A. Cassileth

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth et al. · Blood · 2000 · 1.6K citations

Medicine, Hematology, Oncology +10

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Thomas M. Habermann, Edie Weller, Vicki A. Morrison et al. · Journal of Clinical Oncology · 2006 · 1.4K citations · Full text

Medicine, Geriatric Medicine, Oncology +12

Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

Peter A. Cassileth, David P. Harrington, Frederick R. Appelbaum et al. · New England Journal of Medicine · 1998 · 609 citations · Full text

Medicine, Oncology, Chemotherapy +13

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Michael R. Grever, Kenneth J. Kopecky, M K Foucar et al. · Journal of Clinical Oncology · 1995 · 268 citations

Pharmacy, Oncology, Pharmacotherapy +9

Remissions in Hairy-Cell Leukemia with Pentostatin (2′-Deoxycoformycin)

A. S. D. Spiers, Dirk Moore, Peter A. Cassileth et al. · New England Journal of Medicine · 1987 · 266 citations

Medicine, Oncology, Pharmacotherapy +10